Global Angina (Angina Pectoris) Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In Approval Therapeutics, Companies and Markets
High levels of pipeline activity are being observed in Angina (Angina Pectoris) treatment during 2019. Clinical development activities are being undertaken by more than 10 companies including Angionetics Inc, Beijing CoSci Med-Tech Co.,Ltd, Caladrius Biosciences Inc, G. Pohl-Boskamp GmbH & Co KG , Hemostemix Inc and others.
A Significant contribution to the Angina (Angina Pectoris) pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Angina (Angina Pectoris) pipeline included 11 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Angina (Angina Pectoris) condition and increased access to investments is encouraging growth of Angina (Angina Pectoris) drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Angina (Angina Pectoris) drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Angina (Angina Pectoris) therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Angina (Angina Pectoris) pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Angina (Angina Pectoris). Further, orphan drug status, fast track designation, grants awarded and other special status for Angina (Angina Pectoris) pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Angina (Angina Pectoris) pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Angina (Angina Pectoris) Pipeline candidates-
A Significant contribution to the Angina (Angina Pectoris) pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Angina (Angina Pectoris) pipeline included 11 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Angina (Angina Pectoris) condition and increased access to investments is encouraging growth of Angina (Angina Pectoris) drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Angina (Angina Pectoris) drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Angina (Angina Pectoris) therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Angina (Angina Pectoris) pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Angina (Angina Pectoris). Further, orphan drug status, fast track designation, grants awarded and other special status for Angina (Angina Pectoris) pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Angina (Angina Pectoris) pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Angina (Angina Pectoris) Pipeline candidates-
- Pre-clinical Phase: Discovery, research, pre-clinical
- Early Phase: Phase 1 and Phase 2 Angina (Angina Pectoris) drugs
- Late phase: Phase 3 and in-approval Angina (Angina Pectoris) drugs
- Company overview
- Snapshot
- Angina (Angina Pectoris) therapeutic treatment activities
- Snapshot
- Drug Name
- Alternative Names
- Company
- Originator
- Phase
- Molecule Type
- Orphan Drug Status
- Drug Overview
- Mechanism of Action
- Current Status
- Trial Details
- Pre-clinical trials for each drug candidate
- Clinical trials for each drug candidate
1 TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Angina (Angina Pectoris)- Disease Overview
2.2 Angina (Angina Pectoris)- Pipeline Snapshot
2.3 Angina (Angina Pectoris)- Pipeline Drugs by Phase
2.4 Angina (Angina Pectoris)- Pipeline Drugs by Company
2.5 Angina (Angina Pectoris)- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 Angionetics Inc Angina (Angina Pectoris) Drug Pipeline, H2- 2019
3.2 Beijing CoSci Med-Tech Co.,Ltd Angina (Angina Pectoris) Drug Pipeline, H2- 2019
3.3 Caladrius Biosciences Inc Angina (Angina Pectoris) Drug Pipeline, H2- 2019
3.4 G. Pohl-Boskamp GmbH & Co KG Angina (Angina Pectoris) Drug Pipeline, H2- 2019
3.5 Hemostemix Inc Angina (Angina Pectoris) Drug Pipeline, H2- 2019
3.6 ID Pharma Co Ltd Angina (Angina Pectoris) Drug Pipeline, H2- 2019
3.7 Kuhnil Pharmaceutical Co Ltd Angina (Angina Pectoris) Drug Pipeline, H2- 2019
3.8 Signal Pharma Ltd Angina (Angina Pectoris) Drug Pipeline, H2- 2019
3.9 TSH Biopharm Corporation Ltd Angina (Angina Pectoris) Drug Pipeline, H2- 2019
3.10 ViroMed Co Ltd Angina (Angina Pectoris) Drug Pipeline, H2- 2019
3.11 XyloCor Therapeutics, Inc. Angina (Angina Pectoris) Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Angina (Angina Pectoris)- Phase 1 Drug Details
4.2 Angina (Angina Pectoris)- Phase 1 Drug Overview
4.3 Angina (Angina Pectoris)- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Angina (Angina Pectoris)- Phase 2 Drug Details
5.2 Angina (Angina Pectoris)- Phase 2 Drug Overview
5.3 Angina (Angina Pectoris)- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Angina (Angina Pectoris)- Phase 3 Drug Details
6.2 Angina (Angina Pectoris)- Phase 3 Drug Overview
6.3 Angina (Angina Pectoris)- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Angina (Angina Pectoris)- Pre-clinical Phase Drug Details
7.2 Angina (Angina Pectoris)- Pre-clinical Phase Drug Overview
7.3 Angina (Angina Pectoris)- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Angina (Angina Pectoris)- Disease Overview
2.2 Angina (Angina Pectoris)- Pipeline Snapshot
2.3 Angina (Angina Pectoris)- Pipeline Drugs by Phase
2.4 Angina (Angina Pectoris)- Pipeline Drugs by Company
2.5 Angina (Angina Pectoris)- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 Angionetics Inc Angina (Angina Pectoris) Drug Pipeline, H2- 2019
3.2 Beijing CoSci Med-Tech Co.,Ltd Angina (Angina Pectoris) Drug Pipeline, H2- 2019
3.3 Caladrius Biosciences Inc Angina (Angina Pectoris) Drug Pipeline, H2- 2019
3.4 G. Pohl-Boskamp GmbH & Co KG Angina (Angina Pectoris) Drug Pipeline, H2- 2019
3.5 Hemostemix Inc Angina (Angina Pectoris) Drug Pipeline, H2- 2019
3.6 ID Pharma Co Ltd Angina (Angina Pectoris) Drug Pipeline, H2- 2019
3.7 Kuhnil Pharmaceutical Co Ltd Angina (Angina Pectoris) Drug Pipeline, H2- 2019
3.8 Signal Pharma Ltd Angina (Angina Pectoris) Drug Pipeline, H2- 2019
3.9 TSH Biopharm Corporation Ltd Angina (Angina Pectoris) Drug Pipeline, H2- 2019
3.10 ViroMed Co Ltd Angina (Angina Pectoris) Drug Pipeline, H2- 2019
3.11 XyloCor Therapeutics, Inc. Angina (Angina Pectoris) Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Angina (Angina Pectoris)- Phase 1 Drug Details
4.2 Angina (Angina Pectoris)- Phase 1 Drug Overview
4.3 Angina (Angina Pectoris)- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Angina (Angina Pectoris)- Phase 2 Drug Details
5.2 Angina (Angina Pectoris)- Phase 2 Drug Overview
5.3 Angina (Angina Pectoris)- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Angina (Angina Pectoris)- Phase 3 Drug Details
6.2 Angina (Angina Pectoris)- Phase 3 Drug Overview
6.3 Angina (Angina Pectoris)- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Angina (Angina Pectoris)- Pre-clinical Phase Drug Details
7.2 Angina (Angina Pectoris)- Pre-clinical Phase Drug Overview
7.3 Angina (Angina Pectoris)- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
